Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · February 26, 2020

Effect of the Addition of an Antistaphylococcal β-Lactam in MRSA Bacteremia

JAMA: The Journal of the American Medical Association


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA: The Journal of the American Medical Association
Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial
JAMA 2020 Feb 11;323(6)527-537, SYC Tong, DC Lye, D Yahav, A Sud, JO Robinson, J Nelson, S Archuleta, MA Roberts, A Cass, DL Paterson, H Foo, M Paul, SD Guy, AR Tramontana, GB Walls, S McBride, N Bak, N Ghosh, BA Rogers, AP Ralph, J Davies, PE Ferguson, R Dotel, GL McKew, TJ Gray, NE Holmes, S Smith, MS Warner, S Kalimuddin, BE Young, N Runnegar, DN Andresen, NA Anagnostou, SA Johnson, MD Chatfield, AC Cheng, VG Fowler, BP Howden, N Meagher, DJ Price, SJ van Hal, MVN O'Sullivan, JS Davis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading